assess the risk of cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS). Methods: A total of 81 RRMS patients (mean age 41.09 ± 8.71 years old, 51 women, mean ... central (Cz) latency…
study was to measure cross-sectional changes in hippocampal neurometabolites in Relapsing- Remitting MS (RRMS) patients, compared to Healthy Controls (HCs) and then evaluate the metabolic impact of DMF treatment…
HSCT) and disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow…
Saudi neurologists, held on October 23, 2020, discussed unmet needs in relapsing–remitting MS (RRMS), and the role of ofatumumab as a suitable treatment in the KSA. Multiple unmet needs ... When compared with…
Abstract Objective: To explore the abnormal intrinsic functional hubs in relapsing-remitting multiple sclerosis (RRMS) using degree centrality approach and their relationships with clinical features. Methods: Total of…
enzymatic activity, nitrate-nitrate, lipoperoxide, fluidity membrane) in patients with relapsing remitting multiple sclerosis (RRMS). The MRI of patients with RRMS had a very similar pattern in terms ... lesions. The…
glatiramer acetate (GA) on leptin, resistin, and adiponectin concentrations in relapsing-remitting MS (RRMS) patients. Methods: The study included 154 RRMS patients who were hospitalized in the Department of Neurology…
treatment with Natalizumab has a positive effect on physical disabilities in patients with RRMS. Some studies describe improvements in cognition and fatigue over one year of treatment. Only little ... attention and…
market, essentially, modifying the outcome of acute relapses in relapsing remitting forms of MS (RRMS). Clinical trials in primary and secondary progressive MS forms (PPMS and SPMS) remain less studied ... compared to…
including 29 (65.9%) female and 15 (34.1%) males were studied. 22 patients had RRMS and 22 patients had progressive-relapsing MS (PRMS). In RRMS patients, the EDSS score was significantly ... PRMS patients EDSS was…
treatments (DMT) are available to prevent disease progression for patients with relapsing remitting MS (RRMS). A national guideline recommended that patients with RRMS should be offered DMT to prevent further…
multiple sclerosis (MS) and to compare the two types of MS; Remitting Relapsing MS (RRMS) and progressive MS (PMS) as regards hopelessness, depression, and grief. Methods: It is a cross ... sectional study of 54 MS…
migraine. Methods: We studied patients diagnosed with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), migraine, and ischemic stroke. The number, location and the volume of PVL were identified…
lesions). Results: A total of 460 patients were included: 246 with relapsing-remitting MS (RRMS), 196 Progressive Relapsing MS (PRMS), and 18 PPMS. The patients were 58.6% females with ... Disability Status Scale (EDSS)…
disease characterized by demyelination or axonal loss encompassing several clinical subtypes—Relapsing-Remitting MS (RRMS), Secondary-Progressive MS (SPMS), and Primary-Progressive MS (PPMS). Strategies for treating…
disease biomarker. The study included 124 Saudi subjects, 60 patients with relapsing-remitting MS (RRMS) and 64 healthy individuals. Genomic DNA was extracted from peripheral blood. The mtDNA-encoded
case-control study, the serum levels of Aβ were measured in 48 patients with RRMS and 33 healthy controls using the Enzyme-Linked Immunosorbent Assay (ELISA) technique in Isfahan, Iran ... with SPSS. Results: The mean…
multiple sclerosis (SPMS) were thought to have significantly less intrathecal inflammation than relapsing-remitting (RRMS) MS. Using functional assays and innovative combinatorial cerebrospinal fluid (CSF) biomarkers…
present study an evaluation of serum anti-MOG antibody in relapsing remitting multiple sclerosis (RRMS)patientswas carried out. Method:Serum levels of anti-MOG were measured by ELISA method after
using target cells (K562). Seven patients (aged 38.0 ± 3.21) with stable Relapsing Remitting MS (RRMS) who had previously received alemtuzumab (Lemtrada®), five patients with active MS (aged ... differences for NK cell…
follow up of 12 months did allow a definitive diagnosis of remitting relapsing MS (RRMS) in 21 patients and of NBD in the other 19 among those with CNS inflammation ... patients only while IFN-Ã?³ was elevated in…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.